{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:03:14Z","timestamp":1790863394047,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd011603","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T00:00:00Z","timestamp":1443571200000}}],"reference-count":96,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011603.pub2","type":"journal-article","created":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T20:32:26Z","timestamp":1443645146000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Buprenorphine for neuropathic pain in adults"],"prefix":"10.1002","volume":"2019","author":[{"given":"Philip J","family":"Wiffen","sequence":"first","affiliation":[{"name":"Thame UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Derry","sequence":"additional","affiliation":[{"name":"Oxford Oxfordshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Andrew","family":"Moore","sequence":"additional","affiliation":[{"name":"Plymouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Stannard","sequence":"additional","affiliation":[{"name":"NHS Gloucestershire CCG; Sanger House, 5220 Valiant Court Gloucester Business Park Brockworth UK GL3 4FE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Aldington","sequence":"additional","affiliation":[{"name":"Royal Hampshire County Hospital; Winchester UK SO22 5DG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Cole","sequence":"additional","affiliation":[{"name":"Churchill Hospital, Oxford University Hospitals NHS Trust; Oxford Pain Relief Unit; Old Road Headington Oxford UK OX3 7LE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Knaggs","sequence":"additional","affiliation":[{"name":"University of Nottingham; School of Pharmacy; University Park Nottingham UK NG7 2RD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,30]]},"reference":[{"issue":"2-3","key":"10.1002\/14651858.CD011603.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0304-3959(97)00172-3","article-title":"Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain","volume":"74","author":"Benedetti","year":"1998","journal-title":"Pain"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1163\/156856903321579334","article-title":"Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS) in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study","volume":"15","author":"B\u00f6hme","year":"2003","journal-title":"Pain Clinic"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0003|cit3","first-page":"871","article-title":"Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients","volume":"79","author":"Canneti","year":"2013","journal-title":"Minerva Anestesiologica"},{"issue":"3","key":"10.1002\/14651858.CD011603.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejpain.2008.04.011","article-title":"Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine","volume":"13","author":"Kress","year":"2009","journal-title":"European Journal of Pain"},{"issue":"10","key":"10.1002\/14651858.CD011603.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.clinthera.2007.10.010","article-title":"Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study","volume":"29","author":"Landau","year":"2007","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0006|cit6","unstructured":"Anon Safety and efficacy of buprenorphine transdermal system (BTDS) in subjects with chronic nonmalignant pain, 2012 clinicaltrials.gov\/ct2\/show\/NCT00312195"},{"issue":"4","key":"10.1002\/14651858.CD011603.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1529-8027.2008.00194.x","article-title":"Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies","volume":"13","author":"Penza","year":"2008","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"Suppl V","key":"10.1002\/14651858.CD011603.pub2-BIB0008|cit8","first-page":"11","article-title":"Transdermal buprenorphine in the management of neuropathic pain","volume":"11","author":"Rodriguez-Lopez","year":"2004","journal-title":"Revista de la Sociedad Espa\u00f1ola del Dolor"},{"issue":"1","key":"10.1002\/14651858.CD011603.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0149-2918(03)90019-1","article-title":"Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"25","author":"Sittl","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD011603.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1586\/14737175.5.3.315","article-title":"Transdermal buprenorphine in the treatment of chronic pain","volume":"5","author":"Sittl","year":"2005","journal-title":"Expert Reviews in Neurotherapeutics"},{"issue":"11","key":"10.1002\/14651858.CD011603.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.clinthera.2004.11.008","article-title":"Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study","volume":"26","author":"Sorge","year":"2004","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0012|cit12","first-page":"87","article-title":"Buprenorphine and sustained release morphine - effect and side-effects in chronic use","volume":"4","author":"Bach","year":"1991","journal-title":"Pain Clinic"},{"issue":"1","key":"10.1002\/14651858.CD011603.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1474-4422(11)70281-2","article-title":"Chronic pain: genes, plasticity, and phenotypes","volume":"11","author":"Baron","year":"2012","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD011603.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","article-title":"Prevalence of chronic pain with neuropathic characteristics in the general population","volume":"136","author":"Bouhassira","year":"2008","journal-title":"Pain"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.acpain.2004.08.003","article-title":"Acute pain and the immune system and opioimmunosuppression","volume":"6","author":"Budd","year":"2004","journal-title":"Acute Pain"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2125.1981.tb01189.x","article-title":"Sublingual buprenorphine used post-operatively: clinical observations and preliminary pharmacokinetic analysis","volume":"12","author":"Bullingham","year":"1981","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2165\/00003088-198308040-00004","article-title":"Clinical pharmacokinetics of narcotic agonist-antagonist drugs","volume":"8","author":"Bullingham","year":"1983","journal-title":"Clinical Pharmacology"},{"issue":"21","key":"10.1002\/14651858.CD011603.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/0024-3205(84)90369-2","article-title":"A novel form of dependency of hepatic extraction ratio of opioids in vivo upon the portal vein concentration of drug: comparison of morphine, diamorphine, fentanyl, methadone and buprenorphine in the chronically cannulated cow","volume":"34","author":"Bullingham","year":"1984","journal-title":"Life Sciences"},{"issue":"7","key":"10.1002\/14651858.CD011603.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1474-4422(12)70134-5","article-title":"The role of the immune system in the generation of neuropathic pain","volume":"11","author":"Calvo","year":"2012","journal-title":"Lancet Neurology"},{"issue":"6","key":"10.1002\/14651858.CD011603.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/bja\/aei145","article-title":"Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats","volume":"94","author":"Dahan","year":"2005","journal-title":"British Journal of Anaesthesia"},{"issue":"5","key":"10.1002\/14651858.CD011603.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/bja\/ael051","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan","year":"2006","journal-title":"British Journal of Anaesthesia"},{"issue":"11","key":"10.1002\/14651858.CD011603.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.pain.2014.08.014","article-title":"The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study","volume":"155","author":"Demant","year":"2014","journal-title":"Pain"},{"issue":"9","key":"10.1002\/14651858.CD011603.pub2-BIB0023|cit23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010111","article-title":"Topical capsaicin (low concentration) for chronic neuropathic pain in adults","author":"Derry","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011603.pub2-BIB0024|cit24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007393.pub3","article-title":"Topical capsaicin (high concentration) for chronic neuropathic pain in adults","author":"Derry","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD011603.pub2-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010958.pub2","article-title":"Topical lidocaine for neuropathic pain in adults","author":"Derry","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011603.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"Journal of Pain"},{"issue":"7","key":"10.1002\/14651858.CD011603.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clinical Pharmacokinetics"},{"issue":"8","key":"10.1002\/14651858.CD011603.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ejpain.2005.12.001","article-title":"Effect of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine","volume":"10","author":"Filitz","year":"2006","journal-title":"European Journal of Pain"},{"issue":"7","key":"10.1002\/14651858.CD011603.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/j.1532-2149.2012.00282.x","article-title":"Neuropathic pain needs systematic classification","volume":"17","author":"Finnerup","year":"2013","journal-title":"European Journal of Pain"},{"issue":"2","key":"10.1002\/14651858.CD011603.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurology"},{"issue":"5","key":"10.1002\/14651858.CD011603.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jpainsymman.2013.03.001","article-title":"Buprenorphine therapeutic reviews","volume":"45","author":"Foster","year":"2013","journal-title":"Journal of Pain and Symptom Management"},{"issue":"14","key":"10.1002\/14651858.CD011603.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1212\/WNL.0000000000000839","article-title":"Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology","volume":"83","author":"Franklin","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD011603.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/clpt.1989.10","article-title":"Naloxone reversal of buprenorphine-induced respiratory depression","volume":"45","author":"Gal","year":"1989","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD011603.pub2-BIB0034|cit34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010692.pub2","article-title":"Oxycodone for neuropathic pain and fibromyalgia in adults","author":"Gaskell","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011603.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1399-6576.2007.01486.x","article-title":"Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey","volume":"52","author":"Gustorff","year":"2008","journal-title":"Acta Anaesthesiologica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD011603.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2217\/pmt.11.92","article-title":"Transdermal buprenorphine in clinical practice: a multicenter, postmarketing study in the Czech Republic, with a focus on neuropathic pain components","volume":"2","author":"Hakl","year":"2012","journal-title":"Pain Management"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2296-9-26","article-title":"Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005","volume":"9","author":"Hall","year":"2008","journal-title":"BMC Family Practice"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1471-2296-14-28","article-title":"An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population","volume":"14","author":"Hall","year":"2013","journal-title":"BMC Family Practice"},{"issue":"3","key":"10.1002\/14651858.CD011603.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/bja\/64.3.276","article-title":"Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites","volume":"64","author":"Hand","year":"1990","journal-title":"British Journal of Anaesthesia"},{"issue":"2","key":"10.1002\/14651858.CD011603.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cpt.19","article-title":"Individualized pharmacological treatment of neuropathic pain","volume":"97","author":"Helfert","year":"2015","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0041|cit41","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD011603.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.pain.2009.09.017","article-title":"How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?","volume":"149","author":"Hoffman","year":"2010","journal-title":"Pain"},{"issue":"1","key":"10.1002\/14651858.CD011603.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Jensen TS Baron R Haanp\u00e4\u00e4 M Kalso E Loeser JD Rice AS A new definition of neuropathic pain Pain 2011 2204 5 10.1016\/j.pain.2011.06.017","DOI":"10.1016\/j.pain.2011.06.017"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"f7339","DOI":"10.1136\/bmj.f7339","article-title":"Drugs for neuropathic pain","volume":"347","author":"Kalso","year":"2013","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000110284","article-title":"Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984","volume":"10","author":"Katusic","year":"1991","journal-title":"Neuroepidemiology"},{"issue":"1-3","key":"10.1002\/14651858.CD011603.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pain.2009.08.023","article-title":"Incidence of facial pain in the general population","volume":"147","author":"Koopman","year":"2009","journal-title":"Pain"},{"issue":"6","key":"10.1002\/14651858.CD011603.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1586\/17512433.1.6.729","article-title":"Transdermal buprenorphine in chronic pain: indications and clinical experience","volume":"1","author":"Kusnik","year":"2008","journal-title":"Expert Review of Clinical Pharmacology."},{"key":"10.1002\/14651858.CD011603.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/0003-4819-107-2-224","article-title":"Meta-analysis in clinical research","volume":"107","author":"L'Abb\u00e9","year":"1987","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011603.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s12325-010-0036-3","article-title":"Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain","volume":"27","author":"Lange","year":"2010","journal-title":"Advances in Therapy"},{"issue":"4","key":"10.1002\/14651858.CD011603.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD011603.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.7205\/MILMED-D-12-00310","article-title":"Buprenorphine\/naloxone therapy for opioid refractory neuropathic pain following traumatic amputation: a case series","volume":"178","author":"Licina","year":"2013","journal-title":"Military Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011603.pub2-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007115.pub3","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","author":"Lunn","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD011603.pub2-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006146.pub2","article-title":"Opioids for neuropathic pain","author":"McNicol","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0055|cit55","volume-title":"An Evidence-Based Resource for Pain Relief","author":"McQuay","year":"1998"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0056|cit56","article-title":"Chronic pain","volume-title":"Health Care Needs Assessment, 3rd Series","author":"McQuay","year":"2007"},{"issue":"3","key":"10.1002\/14651858.CD011603.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0304-3959(98)00140-7","article-title":"Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects","volume":"78","author":"Moore","year":"1998","journal-title":"Pain"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0058|cit58","first-page":"15","article-title":"Managing potential publication bias","volume-title":"Systematic Reviews in Pain Research: Methodology Refined","author":"Moore","year":"2008"},{"issue":"3","key":"10.1002\/14651858.CD011603.pub2-BIB0059|cit59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007076.pub2","article-title":"Pregabalin for acute and chronic pain in adults","author":"Moore","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011603.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.pain.2010.05.011","article-title":"\"Evidence\" in chronic pain - establishing best practice in the reporting of systematic reviews","volume":"150","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD011603.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.pain.2010.02.032","article-title":"Chronic low back pain analgesic studies - a methodological minefield","volume":"149","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD011603.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.pain.2010.02.039","article-title":"Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain","volume":"149","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"3","key":"10.1002\/14651858.CD011603.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.pain.2010.07.013","article-title":"Numbers-needed-to-treat analyses - do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials","volume":"151","author":"Moore","year":"2010","journal-title":"Pain"},{"issue":"2","key":"10.1002\/14651858.CD011603.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1136\/ard.2009.107805","article-title":"Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice","volume":"69","author":"Moore","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD011603.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.pain.2010.11.030","article-title":"Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen\/paracetamol combinations after third molar extraction","volume":"152","author":"Moore","year":"2011","journal-title":"Pain"},{"issue":"6","key":"10.1002\/14651858.CD011603.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/EJA.0b013e328343c569","article-title":"Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion","volume":"28","author":"Moore","year":"2011","journal-title":"European Journal of Anaesthesiology"},{"issue":"12","key":"10.1002\/14651858.CD011603.pub2-BIB0067|cit67","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008242.pub2","article-title":"Amitriptyline for neuropathic pain and fibromyalgia in adults","author":"Moore","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011603.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pain.2011.10.004","article-title":"Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses","volume":"153","author":"Moore","year":"2012","journal-title":"Pain"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"f2690","DOI":"10.1136\/bmj.f2690","article-title":"Expect analgesic failure; pursue analgesic success","volume":"346","author":"Moore","year":"2013","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011603.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/anae.12148","article-title":"Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome","volume":"68","author":"Moore","year":"2013","journal-title":"Anaesthesia"},{"issue":"1","key":"10.1002\/14651858.CD011603.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/papr.12050","article-title":"The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain","volume":"14","author":"Moore","year":"2014","journal-title":"Pain Practice"},{"issue":"4","key":"10.1002\/14651858.CD011603.pub2-BIB0072|cit72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007938.pub3","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","author":"Moore","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011603.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/j.1532-2149.2013.00341.x","article-title":"Duloxetine use in chronic painful conditions - individual patient data responder analysis","volume":"18","author":"Moore","year":"2014","journal-title":"European Journal of Pain"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0074|cit74","unstructured":"National Institute for Health and Care Excellence (NICE) Opioids in palliative care, 2012 www.nice.org.uk\/guidance\/cg140"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0075|cit75","unstructured":"National Institute for Health and Care Excellence (NICE) Neuropathic pain - pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings, 2013 www.nice.org.uk\/guidance\/cg173 (accessed 11 June 2015)"},{"issue":"1","key":"10.1002\/14651858.CD011603.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1526-4637.2009.00685","article-title":"Patient-centered perspective on treatment outcomes in chronic pain","volume":"11","author":"O'Brien","year":"2010","journal-title":"Pain Medicine"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2741\/2147","article-title":"Buprenorphine in long-term control of chronic pain in cancer patients","volume":"12","author":"Pace","year":"2007","journal-title":"Frontiers in Bioscience"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0078|cit78","unstructured":"Cochrane Pain, Palliative and Supportive Care Group (PaPaS) author and referee guidance papas.cochrane.org\/papas-documents (accessed 11 June 2015)"},{"issue":"5","key":"10.1002\/14651858.CD011603.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1533-2500.2010.00378.x","article-title":"Current knowledge of buprenorphine and its unique pharmacological profile","volume":"10","author":"Pergolizzi","year":"2010","journal-title":"Pain Practice"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0304-3959(94)90086-8","article-title":"Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion","volume":"56","author":"Rappaport","year":"1994","journal-title":"Pain"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0081|cit81","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"6","key":"10.1002\/14651858.CD011603.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1097\/00000539-200006000-00028","article-title":"The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients","volume":"90","author":"Sacerdote","year":"2000","journal-title":"Anesthesia & Analgesia"},{"issue":"4","key":"10.1002\/14651858.CD011603.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.bbi.2007.12.013","article-title":"Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function","volume":"22","author":"Sacerdote","year":"2008","journal-title":"Brain, Behavior, and Immunity"},{"issue":"5","key":"10.1002\/14651858.CD011603.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gut.27.5.567","article-title":"Effect of modern analgesic drugs (tramadol, pentazocine and buprenorphine) on the bile duct sphincter in man","volume":"27","author":"Staritz","year":"1986","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD011603.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1365-2125.2008.03200","article-title":"Enriched enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review","volume":"66","author":"Straube","year":"2008","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1471-2474-11-150","article-title":"Pregabalin in fibromyalgia - responder analysis from individual patient data","volume":"11","author":"Straube","year":"2010","journal-title":"BMC Musculoskeletal Disorders"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2377-8-9","article-title":"Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials","volume":"8","author":"Sultan","year":"2008","journal-title":"BMC Neurology"},{"issue":"4","key":"10.1002\/14651858.CD011603.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jpain.2005.11.008","article-title":"The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey","volume":"7","author":"Torrance","year":"2006","journal-title":"Journal of Pain"},{"issue":"18","key":"10.1002\/14651858.CD011603.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD011603.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","article-title":"Neuropathic pain in the general population: a systematic review of epidemiological studies","volume":"155","author":"Hecke","year":"2014","journal-title":"Pain"},{"issue":"4","key":"10.1002\/14651858.CD011603.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.neuron.2012.02.008","article-title":"Deconstructing the neuropathic pain phenotype\u00a0to reveal neural mechanisms","volume":"73","author":"Hehn","year":"2012","journal-title":"Neuron"},{"issue":"9859","key":"10.1002\/14651858.CD011603.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011603.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00056-5","article-title":"The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic","volume":"70","author":"Walsh","year":"2003","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1002\/14651858.CD011603.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"414","DOI":"10.5055\/jom.2012.0141","article-title":"Transdermal buprenorphine controls central neuropathic pain","volume":"8","author":"Weiner","year":"2012","journal-title":"Journal of Opioid Management"},{"key":"10.1002\/14651858.CD011603.pub2-BIB0095|cit95","unstructured":"World Health Organization (WHO) Cancer pain relief, 1996 whqlibdoc.who.int\/publications\/9241544821.pdf"},{"issue":"11","key":"10.1002\/14651858.CD011603.pub2-BIB0096|cit96","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010567.pub2","article-title":"Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews","author":"Wiffen","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD011603.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T09:02:12Z","timestamp":1666602132000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011603.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Pain, Palliative and Supportive Care Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,9,30]]},"references-count":96,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011603.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,30]]}}}